Moreno-Fernandez J., Chico A., Martínez-Brocca M.A., Beato-Víbora P.I., Vidal M., Piedra M., Quirós C., Muñoz-Rodríguez J.R.. Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes Mellitus Patients: Results from the Spanish National Registry. Diabetes Technology & Therapeutics. 2022; 24(12)DOI:10.1089/dia.2022.0207. PMID:35947087. IF:5.400(Q1/3D).

Casas J.A.V., Sambo M., López C.L., Durán-Poveda M., García J.R.-V., Santos R.J., Llanos M., Navarro-González E., Aller J., Pubul V., Guadalix S., Crespo G., González C., Zafón C., Navarro M., Santamaría-Sandi J., Segura Á., Gajate P., Gómez-Balaguer M., Valdivia J., Puig-Domingo M., Galofré J.C., Castelo B., Villanueva M.J., Argüelles I., Orcajo-Rincón L.. Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study. European Thyroid Journal. 2022; 11(5)DOI:10.1530/ETJ-21-0111. PMID:35900793. IF:4.700(Q2/3D).

Pérez Pérez A., Ortega Martínez de Victoria E., Arrieta Blanco F., Caixàs Pedragós A., Santos Mazo E., Fernández-Catalina P., Martínez-Hervas S., López-Medina J.A., Suárez-Gutiérrez L., Urgeles Planelles J.R., Gatell Menchén S., Tinahones Madueño F.. First clinical and efficacy data on evolocumab in routine clinical practice in endocrinology and nutrition services in Spain: a retrospective observational study (RETOSS-ENDO). Endocrinologia Diabetes y Nutricion. 2022; 69(7)DOI:10.1016/j.endinu.2021.07.009. PMID:35995680. IF:1.900(Q4/9D).

Tomic D., Morton J.I., Chen L., Salim A., Gregg E.W., Pavkov M.E., Arffman M., Balicer R., Baviera M., Boersma-van Dam E., Brinks R., Carstensen B., Chan J.C.N., Cheng Y.J., Fosse-Edorh S., Fuentes S., Gardiner H., Gulseth H.L., Gurevicius R., Ha K.H., Hoyer A., Jermendy G., Kautzky-Willer A., Keskimäki I., Kim D.J., Kiss Z., Klimek P., Leventer-Roberts M., Lin C.-Y., Lopez-Doriga Ruiz P., Luk A.O.Y., Ma S., Mata-Cases M., Mauricio D., McGurnaghan S., Imamura T., Paul S.K., Peeters A., Pildava S., Porath A., Robitaille C., Roncaglioni M.C., Sugiyama T., Wang K.-L., Wild S.H., Yekutiel N., Shaw J.E., Magliano D.J.. Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study. Lancet Diabetes & Endocrinology. 2022; 10(11)DOI:10.1016/S2213-8587(22)00252-2. PMID:36183736. IF:44.500(Q1/1D).

Puig-Jové, C, Viñals, C, Conget, I, Quirós, C, Vinagre, I, Berrocal, B, Blanco-Carrasco, AJ, Granados, M, Mesa, A, Serés-Noriega, T, Giménez, M, Perea, V, Amor, AJ. Association between the GMI/HbA1c ratio and preclinical carotid atherosclerosis in type 1 diabetes: impact of the fast-glycator phenotype across age groups. Cardiovascular Diabetology. 2025; 24(1)DOI:10.1186/s12933-025-02637-4. PMID:39953520. IF:10.600(Q1/1D).

Gourdy, P, Bonadonna, RC, Mauricio, D, Müller-Wieland, D, Mauquoi, C, Vera, C, Bonnemaire, M, Freemantle, N. Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis. DIABETES OBESITY & METABOLISM. 2025; 27(1)DOI:10.1111/dom.16008. PMID:39420531. IF:5.700(Q1/2D).

Fernandez-Camins, B, Vlacho, B, Canudas, A, Ortega, M, Granado-Casas, M, Perera-LLuna, A, Boluda-Sanson, A, El-Khattabi-Ofkir, Y, Franch-Nadal, J, Mauricio, D. Characterisation of type 2 diabetes subgroups at diagnosis: the COPERNICAN prospective observational cohort study protocol. BMJ Open. 2024; 14(12)DOI:10.1136/bmjopen-2023-083825. PMID:39675821. IF:2.300(Q2/3D).

Beato-Víbora, PI, Chico, A, Moreno-Fernandez, J, Bellido-Castañeda, V, Nattero-Chávez, L, Picón-César, MJ, Martínez-Brocca, MA, Giménez-Alvarez, M, Aguilera-Hurtado, E, Climent-Biescas, E, Azriel-Mir, S, Rebollo-Román, A, Yoldi-Vergara, C, Pazos-Couselo, M, Alonso-Carril, N, Quirós, C. A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-world Setting (vol 47, pg 216, 2024). DIABETES CARE. 2024; 47(12)DOI:10.2337/dc24-er12a. PMID:39265091. IF:16.600(Q1/1D).